1001409-50-2
1001409-50-2 結(jié)構(gòu)式
基本信息
PDK1抑制劑(PDK1 INHIBITOR)
PDK1 inhibitor
PDK1 inhibitor 7
2-dihydro-2-oxo-
4-difluorophenyl)methyl]-N-[(1R)-2-[(2
3-dihydro-2-oxo-1H-benzimidazol-5-yl)oxy]-1-phenylethyl]-1
1-[(3,4-Difluorophenyl)methyl]-N-[(1R)-2-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)oxy]-1-phenylethyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide
3-PyridinecarboxaMide, 1-[(3,4-difluorophenyl)Methyl]-N-[(1R)-2-[(2,3-dihydro-2-oxo-1H-benziMidazol-5-yl)oxy]-1-phenylethyl]-1,2-dihydro-2-oxo-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-14440 | PDK1 抑制劑 MP7 | 1001409-50-2 | 1 mg | 590元 |
| 2026/06/05 | HY-14440 | PDK1 抑制劑 MP7 | 1001409-50-2 | 5mg | 1300元 |
| 2026/06/05 | HY-14440 | PDK1 抑制劑 MP7 | 1001409-50-2 | 10mM * 1mLin DMSO | 1477元 |
常見問題列表
PDK1
Cell counting of U87MG-derived glioma stem cells (GSCs) confirms that Alisertib and, to a minor extent, MP7 (PDK1 inhibitor) are able to decrease the number of viable cells. When combined together, GSC viability is further reduced with respect to single-treated cells. As observed in U87MG cells, when used at the highest concentrations (i.e., 1.5 μM Alisertib and 2.5 μM MP7), a significant enhancement in the number of dead cells is evidenced. Following 72 h treatment, MP7 alone does not show a significant inhibition of glioblastoma multiforme (GBM) proliferation. MP7 has been shown to have only minimal effects on monolayer cell growth in several cancer cell lines, with IC 50 values in the micromolar range.